Ryman Healthcare Ltd.

As of March 31, 2025, Ryman Healthcare Ltd. carries a market capitalization of 1.51B, placing it among publicly traded companies globally. Its enterprise value stands at 2.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ryman Healthcare Ltd.'s next confirmed earnings release is scheduled for November 25, 2026.

As of March 31, 2025, Ryman Healthcare Ltd. has 203.21M shares outstanding.

These figures are as of March 31, 2025. The price-to-sales ratio is 2.61, and the price-to-book ratio stands at 0.62.

These figures are as of March 31, 2025. The EV/Sales ratio of 6.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.47B versus a market cap of 1.51B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2025, Ryman Healthcare Ltd. maintains a current ratio of 0.24, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.78, indicating elevated leverage, while an interest coverage ratio of -1.74 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2025, Ryman Healthcare Ltd. posted a negative return on equity (ROE) of -10.07, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.47, reflecting losses generated across the asset base. The company generates approximately 51,983.89 in revenue per employee across its workforce of 7,800.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended March 31, 2025, Ryman Healthcare Ltd. recorded 125.79M in income tax expense. The company reported a pretax loss of -122.35M and -248.14M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 16, 2026, Ryman Healthcare Ltd.'s stock has declined approximately 29.82% over the past 52 weeks. The 50-day moving average sits at 9.08, while the 200-day moving average is 19.09.

Over the twelve months ended March 31, 2025, Ryman Healthcare Ltd. generated 405.47M in revenue and converted that into -248.14M in net income, yielding earnings per share of -1.75. EBITDA reached -137.89M, while operating income came in at -67.18M.

As of March 31, 2025, Ryman Healthcare Ltd. holds 10.03M in cash and equivalents against 963.00M in total debt, resulting in a net debt position of 945.75M. Total book value stands at 2.42B, with working capital of -382.75M providing operational flexibility.

These figures cover the twelve months ended March 31, 2025.

These figures cover the twelve months ended March 31, 2025. The operating margin of -16.57 and net profit margin of -61.20 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. Total shareholder yield is negative at -3.42, meaning Ryman Healthcare Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ryman Healthcare Ltd.'s most recent stock split took place on February 25, 2025.

As of March 31, 2025, Ryman Healthcare Ltd. has an Altman Z-Score of 0.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.